Treatment algorithms for special cases

BÜLBÜL BASKAN, EMEL

doi:10.4274/turkderm.galenos.2022.10476

Treatment algorithms for special cases

Emel BÜLBÜL BAŞKAN (Uludağ Üniversitesi Tıp Fakültesi, Dermatoloji ve Zührevi Hastalıklar Anabilim Dalı, Bursa, Türkiye)

Türkderm Türk deri hastalıkları ve frengi arşivi

4 1

Yıl: 2022 Cilt: 56 Sayı: 1 Sayfa Aralığı: 80 - 85 Metin Dili: İngilizce DOI: 10.4274/turkderm.galenos.2022.10476 İndeks Tarihi: 18-07-2022

Treatment algorithms for special cases

Öz:

Treatment of psoriasis differs in special cases such as in women who wish to become pregnant, during pregnancy and lactation, in pediatric and geriatric populations, in the presence of obesity or chronic viral diseases, and during the COVID-19 pandemic. Due to their well-known teratogenic effect, neither topical nor systemic use of retinoids is recommended in any period of pregnancy and lactation. Literature data on treatment approaches in psoriasis in children is less than in adults, and safety data usually relate to short-term use. There is a multifactorial relationship between psoriasis and obesity; response to treatment is lower in obese patients with a body mass index greater than 30. It should be noted that the elderly have comorbidities and concomitant drug use, which increases the likelihood of side effects and drug interactions of psoriasis medications. In the presence of a viral disease, many agents used in the treatment of psoriasis carry the risk of exacerbating the infection due to their immunosuppressive properties. In such a case, the option that can be considered apart from topical therapies is narrowband phototherapy. It was observed during the COVID-19 pandemic that there had been no increase in the risk of infection-related mortality and morbidity solely due to biological therapy

Anahtar Kelime:

Özel durumlarda tedavi algoritmaları

Öz:

Psoriasis tedavisi gebe kalmak isteyen kadınlarda, gebelikte, laktasyonda, pediatrik ve geriatrik popülasyonda, obesite ya da kronik viral hastalık varlığında ve COVID-19 pandemisi sırasında özellik arz eder teratojenik etkisi iyi bilinen retinoidlerin gerek topikal gerekse sistemik kullanımı gebeliğin hiçbir döneminde ve laktasyon döneminde önerilmez. Çocuk psoriasis olgularında tedavi yaklaşımlarına yönelik literatür verileri yetişkinlere nazaran daha azdır ve güvenlik verileri sıklıkla kısa dönem kullanımına aittir. Psoriasis ile obezite arasında multifaktöriyel bir ilişki vardır ve vücut kitle indeksi 30’un üzerinde olan obez hastalarda tedaviye yanıt daha düşüktür. Yaşlıların aynı anda birden çok hastalığı ve ilaç kullanımı olduğu ve bunun da psoriasis ilaçlarının yan etkilerinin ve ilaç etkileşimlerinin görülme olasılığını artıracağı unutulmamalıdır. Kronik viral hastalık varlığında psoriasis tedavisinde kullanılan birçok ajanın immün baskılayıcı özelliğinden dolayı enfeksiyonu alevlendirme riski bulunur. Bu durumda topikal tedaviler dışında en çok tercih edilebilecek tedavi dar bant fototerapisidir. COVID-19 pandemisi sırasında psoriasis hastaların özellikle biyolojik tedaviden ötürü enfeksiyon ilişkili mortalite ve morbidite riskinde artış olmadığını gözlenmiştir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Weaterhead S, Robson SC, Reynolds NJ: Management of psoriasis in pregnancy. BMJ 2007;334:1218-20.
2. Bae YS, Van Voorhees AS, Hsu S,et al: Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012;67:459-77.
3. Pham CT, Koo JY: Plasma levels of 8-methoxypsoralen after topical paint PUVA. J Am Acad Dermatol 1993;28:460-6.
4. Reinisch JM, Simon NG, Karow WG, Gandelman R: Prenatal exposure to prednisone in human and animals retards intrauterine growth. Science 1978;202:436-8.
5. Lamarque V, Leleu MF, Monka C, Krupp P: Analysis of 629 pregnancy outcomes in transplant recipients with Sandimmune. Transplant Proc 1997;29:2480.
6. Carter JD, Valeriano J, Vasey FB: Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 2006;33:1014-7.
7. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB: A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36:635-41.
8. Pottinger E, Woolf RT, Exton LS, et al. Exposure to biological therapies during conception and pregnancy: a systematic review. Br J Dermatol. 2018;178:95–102.
9. Nast A, Gisondi P, Ormerod, AD, et al: European S3-Guidelines on the systemic treatment of psoriasis vulgaris-Update 2015-Short versionEDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015;29:2277-94.
10. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections.J Am Acad Dermatol 2019;80:43-53.
11. Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?. Am J Clin Dermatol 2018;19:1-13.
12. Plachouri KM, Georgiou S. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. J Dermatolog Treat 2019;30:668-73.
13. de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM: Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010;62:1013-30.
14. Brune A, Miller DW, Lin P, Cotrim-Russi D, Paller AS: Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007;24:76-80.
15. Steele JA, Choi C, Kwong PC: Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol 2005;53:713-6.
16. Stern RS, Nichols KT: Therapy with orally administered methoxsalen and ultraviolet A radiation during childhood increases the risk of basal cell carcinoma: the PUVA follow-up study. J Pediatr 1996;129:915-7.
17. Jury CS, McHenry P, Burden AD, Lever R, Bilsland D: Narrowband ultraviolet B (UVB) phototherapy in children. Clin Exp Dermatol 2006;31:196-9.
18. Brecher AR, Orlow SJ: Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol 2003;49:171-82.
19. Kaur I, Dogra S, De D, Kanwar AJ: Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol 2008;25:184-8.
20. Harper JI, Ahmed I, Barclay G, et al: Cyclosporin for severe childhood atopic dermatitis:short course versus continuous therapy. Br J Dermatol 2000;142:52-8.
21. Lovell DJ, Reiff A, Ilowite NT, et al: Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
22. Paller AS, Siegfried EC, Langley RG, et al: Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241-51.
23. Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X: Anti-TNF agents for paediatric psoriasis. CochraneDatabase Syst Rev 2015:CD010017.
24. Lansang P, Bergman JN, Fiorillo L, Joseph M, Lara-Corrales I, Marcoux D, McCuaig C, Pope E, Prajapati VH, Li SZ, Landells I, Management of Pediatric Plaque Psoriasis using Biologics, Am Acad Dermatol 2020;82:213-21.
25. Bremmer S, Van Voorhees AS, Hsu S, et al: Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010;63:1058-69.
26. Rucevic I, Perl A, Barisic-Drusko V, Adam-Perl M: The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol 2003;27(Suppl 1):41-8.
27. Roenigk HH Jr, Bergfeld WF, St Jacques R, Owens FJ, Hawk WA: Hepatotoxicity of methotrexate in the treatment of psoriasis. Arch Dermatol 1971;103:250- 61.
28. Rosenberg P, Urwitz H, Johannesson A, et al: Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:1111-8.
29. Griffiths CE, Dubertret L, Ellis CN, et al: Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004;150(Suppl 67):11-23.
30. Gisondi P, Cotena C, Tessari G, Girolomoni G: Anti-tumour necrosis factoralpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008;22:341-4.
31. Reich K, Gottlieb AB, Kimball A, Li S: Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized clinical trials. J Am Acad Dermatol 2006;54(Suppl 1):AB215.
32. Menter A, Tyring SK, Gordon K, et al: Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15.
33. Papp KA, Langley RG, Lebwohl M, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo- controlled trial (PHOENIX 2). Lancet 2008;371:1675-84.
34. Gordon K, Korman N, Frankel E, et al: Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006;54(Suppl 2):101-11.
35. Strober B, Gottlieb A, Leonardi C, Papp K: Levels of response of psoriasis patients with different baseline characteristics treated with etanercept. J Am Acad Dermatol 2006;54(Suppl1):AB220.
36. Potts, GA, Hurley M.Y. Psoriasis in the geriatric population. Clin Geriatr Med 2013:29:373-95.
37. Grozdev IS, Van Voorhees AS, Gottlieb AB, et al: Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2011;65:537-45.
38. Yosipovitch G, Tang MB: Practical management of psoriasis inthe elderly: epidemiology, clinical aspects, quality of life,patient education and treatment options. Drugs Aging 2002;19:847-63.
39. Bressler R, Bahl JJ: Principles of drug therapy for the elderly patient. Mayo Clin Proc 2003;78:1564-77.
40. Turnheim K: Drug dosage in the elderly: is it rational? Drugs Aging 1998;13:357-79.
41. Parslew R, Trauslen J. Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. Eur J Dermatol 2005;15:37-9.
42. Lebwohl M, Ellis C, Gottlieb A, Koo J, et al: Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998;39:464-75.
43. Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018;18:897- 903.
44. Sandhu, V. K., Ighani, A., Fleming, P., Lynde, C. W. Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review. Journal of Cutaneous Medicine and Surgery, 2020;24:174-86.
45. Menon K, Van Voorhees AS, Bebo BF Jr, et al: Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010;62:291-9.
46. Nyfors A, Dahl-Nyfors B, Hopwood D: Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): findings before and after 1 year of therapy in twelve patients; a blind study and review of literature on hepatotoxicity of PUVA. J Am Acad Dermatol 1986;14:43-8.
47. Duvic M, Crane MM, Conant M, Mahoney SE, Reveille JD, Lehrman SN: Ziduvudine improves psoriasis in human immunodeficiency virus-positive males. Arch Dermatol 1994;130:447-51.
48. Fischer T, Schwörer H, Vente C, Reich K, Ramadori G: Clinical improvement of HIV-associated psoriasis parallels reduction of HIV viral load induced by effective antiretroviral therapy. AIDS 1999;13:628-9.
49. Vittorio Luigi De Socio G, Simonetti S, Stagni G: Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scand J Infect Dis 2006;38:74-5.
50. Roenigk HH Jr, Callen JP, Guzzo CA, et al: Effects of acitretin on the liver. J Am Acad Dermatol 1999;41:584-8.
51. Paparizos V, Rallis E, Kirsten L, Kyriakis K: Ustekinumab for the treatment of HIV psoriasis. J Dermatolog Treat 2012;23:398-9.
52. Frankel AJ, Van Voorhees AS, Hsu S et al: Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009;61:1044-55.
53. Calabrese LH, Zein NN, Vassilopoulos D: Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-9.
54. Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF: The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 2013;169:1295-303.
55. Megna M, Ruggiero A, Marasca C, Fabbrocini G. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. Journal of Dermatological Treatment 2020; DOI: 10.1080/09546634.2020.1757605
56. Balogh EA, Heron C, Feldman SR, Huang W. SECURE-Psoriasis: a deidentified registry of psoriasis patients diagnosed with COVID-19.Journal of Dermatological Treatment 2020, DOI: 10.1080/09546634.2020.1753996
57. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment, Journal of the American Academy of Dermatology (2020), doi: https://doi.org/10.1016/ j.jaad.2020.04.085.
58. Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.Dermatol Ther. 2020;27:e13687.
59. Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and immunomodulator/ immunosuppressant use in dermatology. J Am Acad Dermatol. 2020;82:e173-e175.
60. Torres T, Puig L. Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. Am J Clin Dermatol. 2020;21:307-11.

APA	BÜLBÜL BASKAN E (2022). Treatment algorithms for special cases . , 80 - 85. 10.4274/turkderm.galenos.2022.10476
Chicago	BÜLBÜL BASKAN EMEL Treatment algorithms for special cases . (2022): 80 - 85. 10.4274/turkderm.galenos.2022.10476
MLA	BÜLBÜL BASKAN EMEL Treatment algorithms for special cases . , 2022, ss.80 - 85. 10.4274/turkderm.galenos.2022.10476
AMA	BÜLBÜL BASKAN E Treatment algorithms for special cases . . 2022; 80 - 85. 10.4274/turkderm.galenos.2022.10476
Vancouver	BÜLBÜL BASKAN E Treatment algorithms for special cases . . 2022; 80 - 85. 10.4274/turkderm.galenos.2022.10476
IEEE	BÜLBÜL BASKAN E "Treatment algorithms for special cases ." , ss.80 - 85, 2022. 10.4274/turkderm.galenos.2022.10476
ISNAD	BÜLBÜL BASKAN, EMEL. "Treatment algorithms for special cases ". (2022), 80-85. https://doi.org/10.4274/turkderm.galenos.2022.10476

APA	BÜLBÜL BASKAN E (2022). Treatment algorithms for special cases . Türkderm Türk deri hastalıkları ve frengi arşivi, 56(1), 80 - 85. 10.4274/turkderm.galenos.2022.10476
Chicago	BÜLBÜL BASKAN EMEL Treatment algorithms for special cases . Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.1 (2022): 80 - 85. 10.4274/turkderm.galenos.2022.10476
MLA	BÜLBÜL BASKAN EMEL Treatment algorithms for special cases . Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.1, 2022, ss.80 - 85. 10.4274/turkderm.galenos.2022.10476
AMA	BÜLBÜL BASKAN E Treatment algorithms for special cases . Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 80 - 85. 10.4274/turkderm.galenos.2022.10476
Vancouver	BÜLBÜL BASKAN E Treatment algorithms for special cases . Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 80 - 85. 10.4274/turkderm.galenos.2022.10476
IEEE	BÜLBÜL BASKAN E "Treatment algorithms for special cases ." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.80 - 85, 2022. 10.4274/turkderm.galenos.2022.10476
ISNAD	BÜLBÜL BASKAN, EMEL. "Treatment algorithms for special cases ". Türkderm Türk deri hastalıkları ve frengi arşivi 56/1 (2022), 80-85. https://doi.org/10.4274/turkderm.galenos.2022.10476